2008 Key Highlights
- Profitability for the year 2008
- Additional contracts Quinvaxem® and Hepavax-Gene® bring total to $0.5 billion for the period 2007-2009
- Hepavax-Gene® approved in China
- Flu antibody outperforms oseltamivir
- Rabies antibody combination and tuberculosis vaccine enter Phase II
- Important advances made in antibody production using PER.C6® technology
- Record yield of over 27 g/L of an antibody product achieved
- First PER.C6® licensee entered Phase III
- Key license agreements signed
Total revenues and other operating income in 2008
An increase of 33% compared to €213.1 mln in 2007.
Gross margin in 2008
Significant improvement from 34% in 2007.
Net profit in 2008
Compared to a net loss of
€42.9 mln in 2007.